Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons

M Nakamura1, A J Barber, D A Antonetti

  • 1Pennsylvania State Retina Research Group, The Ulerich Ophthalmology Research Center, the Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.

Insights

Excessive glucose flux through the hexosamine biosynthetic pathway (HBP) contributes to diabetic retinopathy by impairing insulin

Area of Science:

  • Biochemistry
  • Cell Biology
  • Neuroscience

Background:

  • Diabetic retinopathy involves neuronal apoptosis, with unknown mechanisms.
  • Insulin may protect retinal neurons via the phosphoinositide 3-kinase/Akt pathway.
  • The hexosamine biosynthetic pathway (HBP) is linked to insulin resistance and diabetic complications.

Purpose of the Study:

  • To investigate if increased glucose flux through the HBP affects insulin action and induces apoptosis in retinal neurons.
  • To elucidate the role of HBP in diabetic neurodegeneration.

Main Methods:

  • R28 retinal neuronal cells were exposed to high glucose or glucosamine.
  • Insulin's neuroprotective effects and Akt phosphorylation were assessed.
  • Levels of UDP-N-acetylhexosamines (UDP-HexNAc) were measured.
  • Effects were compared to L6 muscle cells.

Main Results:

  • High glucose and glucosamine impaired insulin's neuroprotective effects and Akt phosphorylation in R28 cells.
  • Glucosamine induced apoptosis in R28 cells in a dose-dependent manner.
  • HBP activation increased UDP-HexNAc levels, suggesting altered protein glycosylation.

Conclusions:

  • Excessive HBP flux may cause retinal neuronal apoptosis in diabetes through impaired insulin signaling and altered protein glycosylation.
  • The HBP is implicated in the neurodegeneration observed in diabetic retinopathy.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...